Table 3.

Negative prognostic factors in MCL

Clinical feature and genomic aberrationNo. of patientsAll patients evaluable for the characteristic % P
Clinical feature
   LDH level elevated 10 31 32.3 < .001
   Older than 60 y 20 36 55.6 .093
   Stage III/IV 32 35 92.5 .508
   2 or more extranodal sites 24 34 70.6 .057
   WHO performance status of 2 or more 6 30 20.0 .169
Genomic alteration
   8p21 deletion 14 36 38.9 .033
   13q14 deletion 19 36 52.8 .010